Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies-Reference-Cited by-同舟云学术

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies

Published:2008-11 Issue:6 Volume:23 Page:343-356
ISSN:0268-1315
Container-title:International Clinical Psychopharmacology
language:en
Short-container-title:International Clinical Psychopharmacology

Author:

Emsley Robin,Berwaerts Joris,Eerdekens Mariëlle,Kramer Michelle,Lane Rosanne,Lim Pilar,Hough David,Palumbo Joseph

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference43 articles.

1. Delayed-Onset Hypothesis of Antipsychotic Action

2. Relapse in schizophrenia: costs, clinical outcomes and quality of life

3. Consensus Statement: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

4. Factors influencing relapse in the long-term course of schizophrenia

5. A Rating Scale for Drug-Induced Akathisia

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paliperidone-Induced Acute Hyperglycemia Is Caused by Adrenaline Secretion <i>via</i> the Activation of Hypothalamic AMP-Activated Protein Kinase;Biological and Pharmaceutical Bulletin;2022-11-01

2. Dose Adjustment Model of Paliperidone in Patients With Acute Schizophrenia: A post hoc Analysis of an Open-Label, Single-Arm Multicenter Study;Frontiers in Psychiatry;2021-08-23

3. Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study;Schizophrenia Research: Cognition;2020-06

4. Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment;Medicine;2019-01

5. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation;Expert Opinion on Drug Safety;2017-02-09